Opinion: The drug pricing deal isn't really a victory for Dems, or a loss for PhRMA. But it could be a harbinger of change
Although House and Senate Democrats have finally cracked their Mission: Impossible to allow the federal government to negotiate some drug prices, the negotiations will include so few drugs and have so many stipulations attached that the end result may be more of a drop in the ocean than the monsoon that drug price negotiations could’ve been.
Congress is waiting for a CBO score before officially voting, but early estimates point to about $100 billion in drug pricing savings over ten years from the deal. That’s basically the equivalent of what the pharma industry spends on DTC marketing over a decade. Or about five years of what pharma companies spend on marketing to health care professionals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
